A Phase Ia/II Randomized Controlled Trial of Daratumumab Alone Versus
Daratumumab Plus Abatacept for resistant active Antibody-Mediated
Rejection in Kidney Transplant Recipients
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Sponsor type
Laboratory/Research/Testing facility
Therapeutic area
Immune System Diseases
Decision date
08/09/2026
Enrollment target
20
Sites
Spain
Condition studied
active Antibody-Mediated
Rejection in Kidney Transplant Recipients
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.